Our top pick for
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
The Citadel Group Limited is an information technology services business based in Australia. The Citadel Group shares (CGL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. The Citadel Group has a trailing 12-month revenue of around $122 million. If you're looking to buy shares, check out the steps below.
|52-week range||$5.3939 - $5.5|
|50-day moving average||$5.5643|
|200-day moving average||$4.8335|
|Dividend yield||$0.12 (2.19%)|
|Earnings per share (TTM)||$0.122|
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing The Citadel Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of The Citadel Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
The Citadel Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, The Citadel Group shares trade at around 30x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
The Citadel Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.1 million (£0.0 million).
The EBITDA is a measure of a The Citadel Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$122 million|
|Operating margin TTM||3.7%|
|Gross profit TTM||$50.9 million|
|Return on assets TTM||1.17%|
|Return on equity TTM||0.7%|
|Market capitalisation||$432.1 million|
TTM: trailing 12 months
We're not expecting The Citadel Group to pay a dividend over the next 12 months.
Over the last 12 months, The Citadel Group's shares have ranged in value from as little as $5.3939 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while The Citadel Group's is 1.2031. This would suggest that The Citadel Group's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
The Citadel Group Limited, a software and services company, provides software platforms, digital services, and managed services solutions in Australia and internationally. It operates in five segments: Health, Technology, Enterprise Solutions, Professional Services, and Wellbeing. The company primarily offers term managed, software as a service, product sales and installation, consulting, and professional services. It also provides education, specialist consulting and human resource, technology and integration, knowledge management and advisory, systems integration and software development, data management, and information and communications technology managed services, as well as oncology patient management software. Additionally, the company offers radiology and maternity workflow solutions, and health software services. It serves customers in the e-health, defense and national security, government, and tertiary education sectors. The company was founded in 2007 and is based in Symonston, Australia.
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
Westpac shares are up 43% over the past 12 months.
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Shares in the insurer are up just 10% in the last 12 months.
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
The payment services company’s shares are up 16% in the last year.
Everything we know about the Parabellum Resources IPO, plus information on how to buy in.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder.com.au has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product. You can learn more about how we make money here.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.